PDF(Sci-hub)
Abstract：
The purpose of this study is to describe the pharmacologic management of rate and rhythm and assess which factors are associated with the prescription of these drugs in patients with nonvalvular atrial fibrillation (AF) from the Effectiveness, Safety, and Costs in Atrial Fibrillation study.
This retrospective, cross-sectional study describes the pharmacologic rate and rhythm control management strategies adopted during 2012 in all patients diagnosed as having nonvalvular AF in 2007 to 2011. The data source is the Information System for the Improvement of Research in Primary Care database, which is based on primary care electronic health records. To answer the study objectives, 3 multivariate regression models to assess the independent factors associated with the prescription of these drugs were conducted for 2012. The rate and rhythm control drugs assessed were β-blockers, nondihydropyridine calcium channel blockers, antiarrhythmic agents, and digoxin.
A total of 21,304 patients were diagnosed as having nonvalvular AF; 11,638 (54.6%) had at least one heart rate measure during 2012. Of them, 7777 (66.8%) received one or more rate and/or rhythm control drugs during 2012. Most patients (5751 [73.9%] of 7777) received only one drug for rate and/or rhythm control. Rate control agents were the most frequently used in 2012, with β-blockers the most prescribed group (4091 patients [52.6%]). A variety of different variables were associated with the prescription of rate and/or rhythm control drugs in the multivariate regression models.
The most used pharmacologic treatment of rate and rhythm control in our AF population is β-blockers, indicating that a rate control strategy is preferred in our setting, as widely recommended.
This retrospective, cross-sectional study describes the pharmacologic rate and rhythm control management strategies adopted during 2012 in all patients diagnosed as having nonvalvular AF in 2007 to 2011. The data source is the Information System for the Improvement of Research in Primary Care database, which is based on primary care electronic health records. To answer the study objectives, 3 multivariate regression models to assess the independent factors associated with the prescription of these drugs were conducted for 2012. The rate and rhythm control drugs assessed were β-blockers, nondihydropyridine calcium channel blockers, antiarrhythmic agents, and digoxin.
A total of 21,304 patients were diagnosed as having nonvalvular AF; 11,638 (54.6%) had at least one heart rate measure during 2012. Of them, 7777 (66.8%) received one or more rate and/or rhythm control drugs during 2012. Most patients (5751 [73.9%] of 7777) received only one drug for rate and/or rhythm control. Rate control agents were the most frequently used in 2012, with β-blockers the most prescribed group (4091 patients [52.6%]). A variety of different variables were associated with the prescription of rate and/or rhythm control drugs in the multivariate regression models.
The most used pharmacologic treatment of rate and rhythm control in our AF population is β-blockers, indicating that a rate control strategy is preferred in our setting, as widely recommended.
摘要：
这项研究的目的是描述心率和节律的药理学管理，并评估哪些因素与非瓣膜性心房颤动（AF）患者的这些药物处方有关。安全,心房颤动研究中的成本。
这次回顾展,横断面研究描述了2012年期间在2007年至2011年诊断为非瓣膜性房颤的所有患者中采用的药理作用率和节律控制管理策略.数据来源是初级保健数据库研究改进信息系统，这是基于初级保健电子健康记录。为了回答研究目标，2012年进行了3个多元回归模型来评估与这些药物处方相关的独立因素。评估的速率和节律控制药物是β受体阻滞剂，非二氢吡啶类钙通道阻滞剂，抗心律失常药，还有地高辛.
共有21,304例患者被诊断为患有非瓣膜性房颤；2012年期间，有11,638例（54.6%）患者至少有一次心率测量。其中,7777（66.8％）在2012年接受了一种或多种速率和/或节律控制药物。大多数患者（7777人中的5751例[73.9%]）仅接受一种药物以控制速率和/或节律。2012年最常用的是心率控制药物，其中β受体阻滞剂的处方最多(4091例[52.6%])。在多元回归模型中，各种不同的变量与速率和/或节律控制药物的处方相关。
我们房颤人群中最常用的心率和节律控制药物治疗是β受体阻滞剂，表明在我们的设置中，速率控制策略是首选，被广泛推荐。
这次回顾展,横断面研究描述了2012年期间在2007年至2011年诊断为非瓣膜性房颤的所有患者中采用的药理作用率和节律控制管理策略.数据来源是初级保健数据库研究改进信息系统，这是基于初级保健电子健康记录。为了回答研究目标，2012年进行了3个多元回归模型来评估与这些药物处方相关的独立因素。评估的速率和节律控制药物是β受体阻滞剂，非二氢吡啶类钙通道阻滞剂，抗心律失常药，还有地高辛.
共有21,304例患者被诊断为患有非瓣膜性房颤；2012年期间，有11,638例（54.6%）患者至少有一次心率测量。其中,7777（66.8％）在2012年接受了一种或多种速率和/或节律控制药物。大多数患者（7777人中的5751例[73.9%]）仅接受一种药物以控制速率和/或节律。2012年最常用的是心率控制药物，其中β受体阻滞剂的处方最多(4091例[52.6%])。在多元回归模型中，各种不同的变量与速率和/或节律控制药物的处方相关。
我们房颤人群中最常用的心率和节律控制药物治疗是β受体阻滞剂，表明在我们的设置中，速率控制策略是首选，被广泛推荐。
